Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Firat University, Faculty of Medicine, Elazig, Turkey.
Rheumatol Int. 2012 Dec;32(12):3857-62. doi: 10.1007/s00296-011-2302-3. Epub 2011 Dec 23.
The aim of this study was to assess serum levels and clinical significance of soluble CD26 (sCD26) and soluble CD30 (sCD30) in patients with rheumatoid arthritis (RA). Forty-eight patients with RA and 30 healthy controls were enrolled. Serum sCD26 and sCD30 levels were measured using ELISA. Serum sCD26 levels were significantly lower (P = 0.011), whereas sCD30 levels were higher (P = 0.008) in patients with RA than controls. Serum levels of sCD30 correlated significantly with clinical and laboratory parameters of disease activity like erythrocyte sedimentation rate, C-reactive protein, disease activity scores-28 and health assessment questionnaire score; however, sCD26 levels did not correlate any of these activity parameters. These results suggest that serum sCD30 levels increased and correlated significantly with disease activity, indicating a novel follow-up parameter in RA. Serum levels of sCD26 may be lessen but not related to disease activity in RA.
本研究旨在评估类风湿关节炎（RA）患者血清可溶性 CD26（sCD26）和可溶性 CD30（sCD30）的水平及其临床意义。纳入了 48 例 RA 患者和 30 名健康对照者。采用 ELISA 法检测血清 sCD26 和 sCD30 水平。RA 患者血清 sCD26 水平显著降低（P = 0.011），而 sCD30 水平显著升高（P = 0.008）。血清 sCD30 水平与红细胞沉降率、C 反应蛋白、疾病活动评分-28 和健康评估问卷评分等疾病活动的临床和实验室参数显著相关；然而，sCD26 水平与这些活动参数均无相关性。这些结果表明，血清 sCD30 水平升高且与疾病活动显著相关，表明其是 RA 的一种新的随访参数。血清 sCD26 水平可能降低，但与 RA 疾病活动无关。
